Fecal immunochemical test accuracy in familial risk colorectal cancer screening

International Journal of Cancer

Volumn 134, Issue 2, 2014, Pages 367-375

  Castro, Inés ^a   Cubiella, Joaquín ^a   Rivera, Concepciõn ^a   González Mao, Carmen ^b   Vega, Pablo ^a   Soto, Santiago ^a   Hernandez, Vicent ^b   Iglesias, Felipe ^b   Teresa Alves, María ^c   Bujanda, Luis ^d   Fernández Seara, Javier ^a  

^a Complexo Hospitalario Universitario de Ourense ^*  (Spain)

^b UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^c Research Support Unit   (Spain)

^d UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

adenoma; colorectal neoplasms; cost benefit analysis; early detection of cancer; occult blood

Indexed keywords

ADULT; ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER LOCALIZATION; CANCER RISK; CANCER SCREENING; CANCER STAGING; COLONOSCOPY; COLORECTAL CANCER; CONTROLLED STUDY; COST BENEFIT ANALYSIS; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DOUBLE BLIND PROCEDURE; FECES ANALYSIS; FEMALE; FIRST DEGREE RELATIVE; HUMAN; IMMUNOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OCCULT BLOOD; OCCULT BLOOD TEST; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ADENOMA; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; EARLY DETECTION OF CANCER; OCCULT BLOOD;

COLONOSCOPY; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; CROSS-SECTIONAL STUDIES; DOUBLE-BLIND METHOD; EARLY DETECTION OF CANCER; FECES; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; ROC CURVE;

EID: 84887497946     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28353     Document Type: Article

References (40)

1. Ferlay J, Shin H-R, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-917.
2. Levin B, Lieberman D, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-95. (Pubitemid 351615355)
3. Baglietto L, Jenkins MA, Severi G, et al. Measures of familial aggregation depend on definition of family history: meta-analysis for colorectal cancer. J Clin Epidemiol 2006; 59: 114-24. (Pubitemid 43111615)
4. Butterworth AS, Higgins JPT, Pharoah P,. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 2006; 42: 216-27. (Pubitemid 43083493)
5. Dove-Edwin I, Sasieni P, Adams J, et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. Br Med J 2005; 331: 1047.
6. Gimeno-García AZ, Quintero E, Nicolás-Pérez D, et al. Screening for familial colorectal cancer with a sensitive immunochemical fecal occult blood test: a pilot study. Eur J Gastroenterol Hepatol 2009; 21: 1062-7.
7. Winawer S, Fletcher R, Rex D, et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124: 544-60. (Pubitemid 36169269)
8. Atkin WS, Edwards R, Kralj-Hans I, et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624-33.
9. Bujanda L, Sarasqueta C, Zubiaurre L, et al. Low adherence to colonoscopy in the screening of first-degree relatives of patients with colorectal cancer. Gut 2007; 56: 1714-18. (Pubitemid 350206298)
10. Cottet V, Pariente A, Nalet B, et al. Low compliance with colonoscopic screening in first-degree relatives of patients with large adenomas. Aliment Pharmacol Ther 2006; 24: 101-9. (Pubitemid 43894010)
11. Codori AM, Petersen GM, Miglioretti DL, et al. Health beliefs and endoscopic screening for colorectal cancer: potential for cancer prevention. Prev Med 2001; 33: 128-36. (Pubitemid 32744641)
12. Krinstinsson J, Nygaard K, Aadland E, et al. Screening of first degree relatives of patients operated for colorectal cancer: evaluation of fecal calprotectin vs hemoccult II. Digestion 2001; 64: 104-110. (Pubitemid 34701878)
13. Houlston S., Murday V, Harocopos C, et al. Screening and genetic counselling for relatives of patients with colorectal cancer in a family cancer clinic. Br Med J 1990; 301: 366-8. (Pubitemid 20263167)
14. Stephenson BM, Murday VA, Quirke P, et al. Feasibility of family based screening for colorectal neoplasia: experience in one general surgical practice. Gut 1991; 34: 96-100. (Pubitemid 23015958)
15. Rozen P, Levi Z, Hazazi R, et al. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther 2009; 29: 450-7.
16. Greenberg PD, Bertario L, Gnauck R, et al. A prospective multicenter evaluation of new fecal occult blood tests in patients undergoing colonoscopy. Am J Gastroenterol 2000; 95: 1331-8. (Pubitemid 30263533)
17. Park DI, Ryu S, Kim Y-H, et al. Comparison of Guaiac-Based and Quantitative Immunochemical Fecal Occult Blood Testing in a Population at Average Risk Undergoing Colorectal Cancer Screening. Am J Gastroenterol 2010; 105: 2017-25.
18. Hundt S, Haug U, Brenner H,. Comparative Evaluation of Immunochemical Fecal Occult Blood Tests. Ann Intern Med 2007; 150: 162-9.
19. Nakama H, Zhang B, Zhang X,. Evaluation of the optimum cut-off point in immunochemical occult blood testing in screening for colorectal cancer. Eur J Cancer 2001; 37: 398-401. (Pubitemid 32182330)
20. Vilkin A, Rozen P, Levi Z, et al. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test. Am J Gastroenterol 2005; 100: 2519-25.
21. Jover R, Herráiz M, Alarcõn O, et al. Clinical practice guidelines: quality of colonoscopy in colorectal cancer screening. Endoscopy 2012; 44: 444-51.
22. O'Connell JB, Maggard MA, Ko CY,. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004; 96: 1420-5. (Pubitemid 39429665)
23. Levi Z, Rozen P, Hazazi R, et al. A quantitative immunochemical fecal occult blood test for colorectal neoplasia. Ann Intern Med 2007; 146: 244-55. (Pubitemid 351650610)
24. Ferrández A, Thomson C, Blas JM,. Riesgo de neoplasia en familiares de primer grado de pacientes con cáncer colorrectal. Resultados de un programa prospectivo y regional de cribado mediante colonoscopia en poblaciõn de riesgo. Gastroenterol Hepatol 2008; 31: 188-9.
25. Trajman A, Luiz RR,. McNemar chi2 test revisited: comparing sensitivity and specificity of diagnostic examinations. Scand J Clin Lab Invest 2008; 68: 77-80. (Pubitemid 351161511)
26. Ladabaum U, Ferrandez A, Lanas A,. Cost-effectiveness of colorectal cancer screening in high-risk Spanish patients: use of a validated model to inform public policy. Cancer Epidemiol Biomarkers Prev 2010; 19: 2765-76.
27. Whiting P, Rutjes A, Dinnes J, et al. Methods for assessing the quality of diagnostic accuracy studies. Health Technol Assess 2004; 8: 1-234.
28. Elm E von, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008; 61: 344-9. (Pubitemid 351289042)
29. Bossuyt PM, Reitsma JB, Bruns DE, et al. Standards for Reporting of Diagnostic Accuracy. Toward complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Standards for Reporting of Diagnostic Accuracy. Ann Intern Med 2003; 138: 40-4. (Pubitemid 36232093)
30. Rozen P, Comaneshter D, Levi Z, et al. Cumulative evaluation of a quantitative immunochemical fecal occult blood test to determine its optimal clinical use. Cancer 2010; 116: 2115-25.
31. Oort F a, Turenhout ST van, Coupé VMH, et al. Double sampling of a faecal immunochemical test is not superior to single sampling for detection of colorectal neoplasia: a colonoscopy controlled prospective cohort study. BMC Cancer 2011; 11: 434.
32. Morikawa T, Kato J, Yamaji Y, et al. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology 2005; 129: 422-8. (Pubitemid 41096630)
33. Haug U, Hundt S, Brenner H,. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 2010; 105: 682-90.
34. Nakama H, Yamamoto M, Kamijo N, et al. Colonoscopic evaluation of immunochemical fecal occult blood test for detection of colorectal neoplasia. Hepatogastroenterology 1999; 46: 228-31. (Pubitemid 29154752)
35. Nakama H, Zhang B, Fattah a S,. A cost-effective analysis of the optimum number of stool specimens collected for immunochemical occult blood screening for colorectal cancer. Eur J Cancer 2000; 36: 647-50. (Pubitemid 30156851)
36. Levi Z, Rozen P, Hazazi R, et al. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer? Aliment Pharmacol Ther 2006; 24: 1475-81. (Pubitemid 44657125)
37. Terhaar Sive Droste JS, Turenhout ST van, et al. Faecal immunochemical test accuracy in patients referred for surveillance colonoscopy: a multi-centre cohort study. BMC Gastroenterol 2012; 12: 94.
38. Grupo de trabajo de la guía de práctica clínica de prevenciõn del cáncer colorrectal. Actualizaciõn 2009. Prevenciõn del Cáncer Colorrectal. Guía de práctica clínica. Barcelona: Asociaciõn Española de Gastroenterología, Sociedad Española de Medicina de Familia y Comunitaria, y Centro Cochrane Iberoamericano; 2009. Programa de Elaboraciõn de Guías de Práctica.
39. Ramsey SD, Wilschut J, Boer R, et al. A decision-analytic evaluation of the cost-effectiveness of family history-based colorectal cancer screening programs. Am J Gastroenterol 2010; 105: 1861-9.
40. Kaminski MF, Regula J, Kraszewska E, et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362: 1795-803.